Should I Buy RADX? RADX 2026 Analysis

Should You Buy Radiopharm Theranostics Ltd (RADX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

4.590

1 Day change

2.00%

52 Week Range

16.250

Analysis Updated At

2026/04/24

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Radiopharm Theranostics Ltd (RADX) does not present a strong buy opportunity at the moment. The technical indicators are neutral, there are no significant trading trends or catalysts, and no proprietary trading signals are active. For a beginner investor with a long-term strategy, this stock does not currently align with a strong investment opportunity.

Technical Analysis

The MACD is positive but contracting (0.0259), RSI is neutral at 42.31, and moving averages are converging. The stock is trading near its pivot level (4.618), with resistance at 4.774 and support at 4.461. No clear bullish or bearish signals are present.

Positive Catalysts

NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

No significant negative catalysts, but the lack of news, trading trends, and financial data limits visibility.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available for review.

3 Analyst Rating

Wall Street analysts forecast RADX stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 4.500

Low

Averages

20.33

High

Current: 4.500

Low

Averages

20.33

High

Maxim

Michael Okunewitch

NULL -> Buy

upgrade

$12 -> $15

AI Analysis

2025-12-17

Reason

Maxim

Michael Okunewitch

Price Target

$12 -> $15

AI Analysis

2025-12-17

upgrade

NULL -> Buy

Reason

Maxim analyst Michael Okunewitch raised the firm's price target on Radiopharm to $15 from $12 and keeps a Buy rating on the shares. The firm cites the company having announced positive results on its primary endpoint in an interim analysis of the first 12 patients in the Phase 2b study of RAD 101, as the study demonstrated concordance with MRI in 92% of patients treated with RAD 101 as a PET imaging agent for brain metastases, the analyst tells investors in a research note. The initial data emerging from the Phase 2b study of RAD 101 in brain metastasis imaging is highly encouraging and de-risks Radopharm's potential to address the $500M market opportunity in brain mets diagnostics and monitoring, the firm added.

B. Riley

Buy

maintain

$13 -> $16

2025-12-16

Reason

B. Riley

Price Target

$13 -> $16

2025-12-16

maintain

Buy

Reason

B. Riley raised the firm's price target on Radiopharm to $16 from $13 and keeps a Buy rating on the shares. Radiopharm reported positive interim Phase 2b imaging data for RAD101 in brain metastases, with 92% MRI concordance and clear, selective tumor uptake consistent with prior Phase 2a results, the analyst tells investors in a research note. Enrollment is over 50% in the 30-patient study, with final data expected in the first half of 2026 to inform Phase 3 design ahead of a planned FDA meeting in mid-2026, B. Riley adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RADX

Unlock Now

RADX Should I Buy

RADX Should I Buy

Should You Buy Radiopharm Theranostics Ltd (RADX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch